Mesmer Pharmaceuticals

Mesmer Pharmaceuticals is a biotechnology company focused on developing therapies that target the innate immune system to treat cancer. The company's primary approach involves inhibiting Myeloid-Derived Suppressor Cells (MDSCs), which create an immunosuppressive environment that protects tumors from the immune system. Its lead asset, INB03, is a dominant-negative inhibitor of soluble Tumor Necrosis Factor (sTNF) designed to neutralize MDSCs and enhance the efficacy of checkpoint inhibitors and other immunotherapies. Mesmer was acquired by INmune Bio in 2019, integrating its specialized MDSC-targeting platform into INmune's broader oncology and inflammation pipeline. The company's technology originated from a licensing agreement with Xencor for their DN-TNF platform.